Aurora kinase mRNA expression is reduced with increasing gestational age and in severe early onset fetal growth restriction.
Aurora kinase
Cellular senescence
FGR
Preeclampsia
Journal
Placenta
ISSN: 1532-3102
Titre abrégé: Placenta
Pays: Netherlands
ID NLM: 8006349
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
31
01
2020
revised:
05
04
2020
accepted:
20
04
2020
pubmed:
27
5
2020
medline:
2
6
2021
entrez:
27
5
2020
Statut:
ppublish
Résumé
Oxidative damage and biochemical ageing are implicated in placental dysfunction and potentially fetal death. Cellular senescence may play a role in the pathophysiology of fetal growth restriction (FGR) and preeclampsia (PE). Aurora kinases (AURKA, B and C) are important regulators of cellular division in mitosis and meiosis with implications in cellular senescence. We aimed to investigate whether aurora kinase expression is altered with placental dysfunction or placental ageing. Placenta and blood was obtained across gestation from pregnancies complicated by PE, FGR or both PE and FGR, as well as gestation-matched control samples. Expression of AURKA, B and C mRNA was examined using real time qPCR in both the placenta and maternal circulation. Placental aurora kinase expression decreased as gestation progressed: AURKA and AURKB were significantly reduced at 37-40 weeks, whereas AURKC was significantly reduced at 34-37 weeks, when compared to <34 weeks. In the maternal circulation, the mRNA level of AURKB was significantly reduced at >40 weeks compared to <34 weeks gestation. A significant reduction in AURKC was seen in FGR pregnancies <34 weeks compared to gestation-matched controls. Placental AURK expression is reduced with increased gestation. Circulating AURKB mRNA reduces at >40 weeks gestation, when compared to <34 weeks. AURKC is significantly reduced in placentas from pregnancies complicated by severe early onset (<34 weeks) FGR compared with gestation-matched controls. The functional role of aurora kinase in the placenta and in gestational age warrants further investigation.
Identifiants
pubmed: 32452402
pii: S0143-4004(20)30115-6
doi: 10.1016/j.placenta.2020.04.012
pmc: PMC8500538
mid: NIHMS1744694
pii:
doi:
Substances chimiques
RNA, Messenger
0
Aurora Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
53-61Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM112801
Pays : United States
Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.
Références
Med J Aust. 2012 Sep 3;197(5):291-4
pubmed: 22938128
FEBS Lett. 2011 Nov 16;585(22):3569-76
pubmed: 22024481
Free Radic Biol Med. 2017 Feb;103:177-187
pubmed: 28017898
Curr Biol. 2018 Nov 5;28(21):3458-3468.e5
pubmed: 30415701
Lancet. 2008 Jan 19;371(9608):261-9
pubmed: 18207020
Clin Med Insights Pediatr. 2016 Jul 14;10:67-83
pubmed: 27441006
J Pathol. 2011 Oct;225(2):243-54
pubmed: 21710690
J Pregnancy. 2018 Jun 28;2018:2632637
pubmed: 30050697
Cell. 2007 Jul 27;130(2):223-33
pubmed: 17662938
Proc Natl Acad Sci U S A. 2012 Aug 14;109(33):E2215-22
pubmed: 22778418
Oncotarget. 2017 Apr 4;8(14):23937-23954
pubmed: 28147341
Am J Obstet Gynecol. 2018 Feb;218(2S):S762-S773
pubmed: 29275823
Am J Obstet Gynecol. 2017 Oct;217(4):441.e1-441.e14
pubmed: 28645573
Oncol Res. 2012;20(5-6):241-50
pubmed: 23581231
Front Cell Dev Biol. 2015 Aug 20;3:50
pubmed: 26347867
Placenta. 2014 Jan;35(1):9-22
pubmed: 24290528
Prog Mol Biol Transl Sci. 2017;145:163-179
pubmed: 28110750
Lancet. 2001 Jan 6;357(9249):53-6
pubmed: 11197372
Obstet Gynecol. 2013 Nov;122(5):1122-1131
pubmed: 24150027
Anticancer Drugs. 2017 Sep;28(8):841-851
pubmed: 28639950
PLoS One. 2013 Nov 25;8(11):e78487
pubmed: 24282500
Nat Commun. 2012;3:1072
pubmed: 22990868
Pathol Int. 2006 Jul;56(7):375-80
pubmed: 16792546
Placenta. 2013 Apr;34(4):320-4
pubmed: 23395459
Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):829-39
pubmed: 20863917